AXS-05 for Alzheimer Agitation: What to Know Before the April 30, 2026 PDUFA Decision

AXS-05 (dextromethorphan-bupropion) faces an FDA decision on April 30, 2026 for Alzheimer disease agitation. Trial results were mixed across four phase 3 studies — here is what clinicians should know about its likely place in care.

April 26, 2026 · 4 min read

Why AXS-05 Is in the News Right Now

The FDA’s decision on AXS-05 for Alzheimer disease (AD) agitation is due April 30, 2026 — four days from publication. Axsome Therapeutics submitted the supplemental new drug application (sNDA) in late 2025; the FDA accepted the filing and granted priority review on December 31, 2025.

If approved, AXS-05 — an oral fixed-dose combination of dextromethorphan hydrobromide and bupropion hydrochloride — would become only the second drug FDA-approved specifically for AD agitation. The first was brexpiprazole (Rexulti), an atypical antipsychotic approved in May 2023 with a boxed warning for increased mortality in elderly patients with dementia-related psychosis. AXS-05 is not an antipsychotic.

The Background

Agitation — pacing, verbal aggression, physical aggression, disinhibition — affects up to 70% of patients with AD. It is a leading driver of nursing-home placement and accelerated functional decline.

AXS-05 is already approved as Auvelity for major depressive disorder (since August 2022). The dextromethorphan component is an N-methyl-D-aspartate (NMDA) receptor antagonist, sigma-1 receptor agonist, and serotonin/norepinephrine transporter inhibitor. Bupropion serves dual roles: it raises dextromethorphan plasma exposure by inhibiting CYP2D6 metabolism and adds dopamine and norepinephrine reuptake inhibition. AXS-05 has held FDA breakthrough therapy designation for AD agitation since June 2020.

The Evidence So Far on AXS-05 for Alzheimer Agitation

The sNDA rests on four randomized, controlled phase 3 trials and a long-term safety study. Three of four met their primary endpoints; one did not.

ADVANCE-1 (n=366; phase 2/3) randomized patients to AXS-05, bupropion alone, or placebo for 5 weeks. AXS-05 reduced the Cohen-Mansfield Agitation Inventory (CMAI) total score by 15.4 points versus 11.5 with placebo (p=0.010), and outperformed bupropion alone (p<0.001), establishing component contribution.

ADVANCE-2 (n=408) randomized patients to AXS-05 or placebo for 5 weeks. The trial did not reach statistical significance on the primary CMAI endpoint (13.8-point vs 12.6-point reduction), although results numerically favored AXS-05 across most secondary outcomes. ADVANCE-2 was the only one of the four pivotal trials to miss its primary endpoint.

ACCORD-1 (n=178) used a randomized-withdrawal design: 9 weeks of open-label AXS-05, with responders randomized to continue AXS-05 or switch to placebo for up to 26 weeks. AXS-05 produced a 3.6-fold lower relapse risk versus placebo (hazard ratio 0.276; p=0.014); relapse occurred in 7.5% on AXS-05 versus 25.9% on placebo. ACCORD-2 (n=295) replicated the result with a similar effect size and p=0.001.

Across the program, AXS-05 was generally well tolerated. The most common adverse events were somnolence, dizziness, and diarrhea. There was no signal for cognitive decline, increased falls, sedation, or treatment-related deaths in 456 patients followed for up to 12 months in the long-term safety study.

Where Experts Disagree on AXS-05

The mixed efficacy across the four pivotal trials is the central debate. Three of four randomized trials hit their primary endpoint, and the relapse-prevention design used in ACCORD-1 and ACCORD-2 is broadly considered the more rigorous test for a chronic-symptom indication.

Optimistic clinicians, including HERCULES program lead investigators and AAN 2024 commentators, have framed ADVANCE-2’s miss as likely a high placebo-response artifact in a 5-week parallel-group setting, and have emphasized that AXS-05 — unlike brexpiprazole — would not carry a class antipsychotic mortality boxed warning.

More cautious independent voices have noted three concerns. ADVANCE-2’s missed primary endpoint may weigh heavily in the FDA’s review, particularly given the precedent that brexpiprazole’s approval was supported by two clearly positive parallel-group trials. The randomized-withdrawal design selected for responders before randomization, which inflates apparent efficacy compared with an all-comers design. And the longest controlled exposure remains 26 weeks, leaving long-term cardiovascular and seizure-threshold safety as open questions in a frail population.

The Practical Question for Clinicians

The practical question is how AXS-05, if approved on April 30, would fit into the AD agitation toolkit. Three considerations matter.

First, comparison to brexpiprazole. Brexpiprazole’s CMAI separation versus placebo was modest at 12 weeks, and its label carries a class boxed warning for increased mortality in elderly patients with dementia-related psychosis treated with antipsychotics. AXS-05 is not an antipsychotic and would not carry that warning. For families and clinicians wary of antipsychotics in older patients, that distinction matters.

Second, drug interactions and contraindications. Bupropion is a strong CYP2D6 inhibitor and lowers the seizure threshold. Concurrent prescriptions of CYP2D6 substrates — many SSRIs, certain opioids and beta-blockers — warrant review. Patients with seizure history, eating disorders, or recent abrupt sedative or alcohol cessation are typically excluded.

Third, place in line. Non-pharmacological behavioral and environmental interventions remain first-line per AGS Beers Criteria and Alzheimer’s Association guidance. AXS-05 — like brexpiprazole — would be reserved for patients with persistent, clinically significant agitation despite those measures.

What to Watch For

The April 30, 2026 PDUFA decision on AXS-05 — approval, complete response letter, or extension
Any restrictive language in a potential label about ADVANCE-2’s missed primary endpoint, dosing limits, or required REMS
Long-term mortality, fall, and seizure data once real-world use accumulates outside trial selection
CMS coverage signals for AXS-05 in nursing-home and long-term care settings, where most AD agitation prescribing occurs

Sources

Axsome Therapeutics. Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation. Press release, December 31, 2025. Axsome FDA Acceptance and Priority Review Announcement (December 31, 2025)
NeurologyLive. Supplemental New Drug Application Submitted for AXS-05 as Treatment for Alzheimer Disease Agitation. March 5, 2026. NeurologyLive — AXS-05 sNDA Submission and Phase 3 Program Summary
Psychiatric Times. A Review of Data on AXS-05 for Alzheimer Disease Agitation in Advance of Next Week’s PDUFA Date. April 24, 2026. Psychiatric Times — Pre-PDUFA Data Review (April 2026)
Cummings J, Lyketsos C, Tariot P, et al. Efficacy and Safety of AXS-05 in Agitation Associated with Alzheimer’s Disease: Results from ACCORD, a Phase 3, Double-blind, Placebo-controlled, Relapse Prevention Trial (PL5.004). Neurology. 2024. Cummings et al., Neurology 2024 — ACCORD Trial Abstract
US Food and Drug Administration. FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer’s Disease. May 11, 2023. FDA Brexpiprazole Approval Announcement (May 2023)
Anderson P. Novel Agent Curbs Alzheimer’s-Related Agitation. Medscape Medical News, April 23, 2024. Medscape — ACCORD Trial Coverage with Independent Commentary
ALZFORUM. AXS-05 Therapeutics Profile. Last updated January 2025. ALZFORUM — AXS-05 Mechanism, Trials, and Long-Term Safety Summary